An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies-Reference-Cited by-同舟云学术

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies

Published:2020-01-07 Issue:1 Volume:15 Page:e0227356
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Perrier Alexandre,Boelle Pierre-Yves,Chrétien Yves,Gligorov Joseph,Lotz Jean-Pierre,Brault Didier,Comperat Eva,Lefèvre Guillaume,Boissan Mathieu^ORCID

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference47 articles.

1. Cancer statistics, 2016;RL Siegel;CA Cancer J Clin,2016

2. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines;MV Shah;J Clin Oncol,2016

3. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene;DJ Slamon;Science,1987

4. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;EH Romond;N Engl J Med,2005

5. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;SM Swain;N Engl J Med,2015

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients;Journal of Experimental & Clinical Cancer Research;2024-06-29

2. Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial;Clinical and Translational Medicine;2024-05

3. Involvement of FAM170B-AS1, hsa-miR-1202, and hsa-miR-146a-5p in breast cancer;Cancer Biomarkers;2024-04-15

4. Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer;Cancer Cell International;2024-03-19

5. Biomarker-specific biosensors revolutionise breast cancer diagnosis;Clinica Chimica Acta;2024-03